A better understanding of the anti-SARS-CoV-2 immune response is necessary to finely
evaluate commercial serological assays but also to predict protection against reinfection and …

Summary SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19, making
them a focus of vaccine design. A safety concern regarding SARS-CoV-2 antibodies is …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health
threat for which preventive and therapeutic agents are urgently needed. Neutralizing …

BACKGROUND SARS-CoV-2–specific antibodies may protect from reinfection and disease,
providing rationale for administration of plasma containing SARS-CoV-2–neutralizing …

The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019
(COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed …

In the absence of approved drugs or vaccines, there is a pressing need to develop tools for
therapy and prevention of Covid-19. Human monoclonal antibodies have very good …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

Currently, neutralizing antibody and vaccine strategies have been developed by targeting
the SARS-CoV-2 strain identified during the early phase of the pandemic. Early studies …

The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused
a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide
causing a pandemic with millions of infected people and deaths. Currently, the scientific …